Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...

Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Cullinan Therapeutics in a report released ...

Leerink upgraded Doximity (DOCS) to Outperform from Market Perform with a price target of $90, up from $60. While “admittedly late on this,” ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied promised bonuses and deferred grant awards worth millions of dollars.

What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street’s best analysts ...

The company built a digital platform for medical professionals that helps carry out telehealth appointments with patients, ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

Q4 2024. Management View. CEO Mark Tarr emphasized strong financial performance in Q4 2024, with revenue increasing ...

Chair and CEO of Insmed Inc. (NASDAQ:INSM), recently executed a significant stock transaction amid the company's impressive 178% stock surge over the past year. According to a recent SEC filing, Lewis ...

Michael Alexander Smith, the Chief Legal Officer of Insmed Inc. (NASDAQ:INSM), has recently sold a significant portion of his holdings in the company. According to a recent SEC filing, Smith sold ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...